Differential effect of phosphodiesterase-3 inhibitors on sympathetic hyperinnervation in healed rat infarcts

Tsung-Ming Lee, Shinn Zong Lin, Nen Chung Chang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The effect of phosphodiesterase-3 (PDE-3) inhibitors on arrhythmia remains controversial, so the purpose of this study was to determine their differential effects on sympathetic hyperinnervation and the involved mechanisms in a rat model of myocardial infarction. Methods and Results: After ligating the coronary artery, male Wistar rats were randomized to cilostazol or milrinone, chemically unrelated inhibitors of PDE-3, or vehicle for 4 weeks. The postinfarction period was associated with increased myocardial norepinephrine levels and oxidant release, as measured by myocardial superoxide level and dihydroethidine fluorescence staining. Infarcted rats in the milrinone- and cilostazol-treated groups had favorable ventricular remodeling with similar potency. Compared with milrinone, cilostazol significantly increased interstitial adenosine levels and reduced the production of myocardial cAMP and superoxide. Cilostazol significantly blunted sympathetic hyperinnervation, as assessed by immunofluorescent analysis of sympathetic innervation, and western blotting and real-time quantitative RT-PCR of nerve growth factor. Furthermore, the inhibitory effect of cilostazol on nerve growth factor was reversed by 8-cyclopentyl-1,3-dipropylxanthine, a selective A1 receptor antagonist, and enhanced by tempol administration. In spite of similar arrhythmic vulnerability during programmed stimulation in both the vehicle- and cilostazol-treated groups, cilostazol did not have proarrhythmic effects compared with milrinone. Conclusions: Unlike milrinone, cilostazol has therapeutic neutrality in arrhythmias because of adenosine uptake inhibition, which antagonizes the PDE-3-induced increase of sympathetic reinnervation via mediation of an adenosine A1 receptor-mediated antioxidation.

Original languageEnglish
Pages (from-to)366-376
Number of pages11
JournalCirculation Journal
Volume78
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Phosphodiesterase 3 Inhibitors
Milrinone
Nerve Growth Factor
Superoxides
Adenosine
Cardiac Arrhythmias
Adenosine A1 Receptors
Ventricular Remodeling
cilostazol
Phosphoric Diester Hydrolases
Oxidants
Wistar Rats
Real-Time Polymerase Chain Reaction
Coronary Vessels
Norepinephrine
Fluorescence
Western Blotting
Myocardial Infarction
Staining and Labeling

Keywords

  • Arrhythmia
  • Myocardial infarction
  • Phosphodiesterase-3 inhibitors
  • Remodeling
  • Sympathetic innervation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Differential effect of phosphodiesterase-3 inhibitors on sympathetic hyperinnervation in healed rat infarcts. / Lee, Tsung-Ming; Lin, Shinn Zong; Chang, Nen Chung.

In: Circulation Journal, Vol. 78, No. 2, 2014, p. 366-376.

Research output: Contribution to journalArticle

@article{735cd77ab99e4bf796afbc1a4578c997,
title = "Differential effect of phosphodiesterase-3 inhibitors on sympathetic hyperinnervation in healed rat infarcts",
abstract = "Background: The effect of phosphodiesterase-3 (PDE-3) inhibitors on arrhythmia remains controversial, so the purpose of this study was to determine their differential effects on sympathetic hyperinnervation and the involved mechanisms in a rat model of myocardial infarction. Methods and Results: After ligating the coronary artery, male Wistar rats were randomized to cilostazol or milrinone, chemically unrelated inhibitors of PDE-3, or vehicle for 4 weeks. The postinfarction period was associated with increased myocardial norepinephrine levels and oxidant release, as measured by myocardial superoxide level and dihydroethidine fluorescence staining. Infarcted rats in the milrinone- and cilostazol-treated groups had favorable ventricular remodeling with similar potency. Compared with milrinone, cilostazol significantly increased interstitial adenosine levels and reduced the production of myocardial cAMP and superoxide. Cilostazol significantly blunted sympathetic hyperinnervation, as assessed by immunofluorescent analysis of sympathetic innervation, and western blotting and real-time quantitative RT-PCR of nerve growth factor. Furthermore, the inhibitory effect of cilostazol on nerve growth factor was reversed by 8-cyclopentyl-1,3-dipropylxanthine, a selective A1 receptor antagonist, and enhanced by tempol administration. In spite of similar arrhythmic vulnerability during programmed stimulation in both the vehicle- and cilostazol-treated groups, cilostazol did not have proarrhythmic effects compared with milrinone. Conclusions: Unlike milrinone, cilostazol has therapeutic neutrality in arrhythmias because of adenosine uptake inhibition, which antagonizes the PDE-3-induced increase of sympathetic reinnervation via mediation of an adenosine A1 receptor-mediated antioxidation.",
keywords = "Arrhythmia, Myocardial infarction, Phosphodiesterase-3 inhibitors, Remodeling, Sympathetic innervation",
author = "Tsung-Ming Lee and Lin, {Shinn Zong} and Chang, {Nen Chung}",
year = "2014",
doi = "10.1253/circj.CJ-13-0749",
language = "English",
volume = "78",
pages = "366--376",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "2",

}

TY - JOUR

T1 - Differential effect of phosphodiesterase-3 inhibitors on sympathetic hyperinnervation in healed rat infarcts

AU - Lee, Tsung-Ming

AU - Lin, Shinn Zong

AU - Chang, Nen Chung

PY - 2014

Y1 - 2014

N2 - Background: The effect of phosphodiesterase-3 (PDE-3) inhibitors on arrhythmia remains controversial, so the purpose of this study was to determine their differential effects on sympathetic hyperinnervation and the involved mechanisms in a rat model of myocardial infarction. Methods and Results: After ligating the coronary artery, male Wistar rats were randomized to cilostazol or milrinone, chemically unrelated inhibitors of PDE-3, or vehicle for 4 weeks. The postinfarction period was associated with increased myocardial norepinephrine levels and oxidant release, as measured by myocardial superoxide level and dihydroethidine fluorescence staining. Infarcted rats in the milrinone- and cilostazol-treated groups had favorable ventricular remodeling with similar potency. Compared with milrinone, cilostazol significantly increased interstitial adenosine levels and reduced the production of myocardial cAMP and superoxide. Cilostazol significantly blunted sympathetic hyperinnervation, as assessed by immunofluorescent analysis of sympathetic innervation, and western blotting and real-time quantitative RT-PCR of nerve growth factor. Furthermore, the inhibitory effect of cilostazol on nerve growth factor was reversed by 8-cyclopentyl-1,3-dipropylxanthine, a selective A1 receptor antagonist, and enhanced by tempol administration. In spite of similar arrhythmic vulnerability during programmed stimulation in both the vehicle- and cilostazol-treated groups, cilostazol did not have proarrhythmic effects compared with milrinone. Conclusions: Unlike milrinone, cilostazol has therapeutic neutrality in arrhythmias because of adenosine uptake inhibition, which antagonizes the PDE-3-induced increase of sympathetic reinnervation via mediation of an adenosine A1 receptor-mediated antioxidation.

AB - Background: The effect of phosphodiesterase-3 (PDE-3) inhibitors on arrhythmia remains controversial, so the purpose of this study was to determine their differential effects on sympathetic hyperinnervation and the involved mechanisms in a rat model of myocardial infarction. Methods and Results: After ligating the coronary artery, male Wistar rats were randomized to cilostazol or milrinone, chemically unrelated inhibitors of PDE-3, or vehicle for 4 weeks. The postinfarction period was associated with increased myocardial norepinephrine levels and oxidant release, as measured by myocardial superoxide level and dihydroethidine fluorescence staining. Infarcted rats in the milrinone- and cilostazol-treated groups had favorable ventricular remodeling with similar potency. Compared with milrinone, cilostazol significantly increased interstitial adenosine levels and reduced the production of myocardial cAMP and superoxide. Cilostazol significantly blunted sympathetic hyperinnervation, as assessed by immunofluorescent analysis of sympathetic innervation, and western blotting and real-time quantitative RT-PCR of nerve growth factor. Furthermore, the inhibitory effect of cilostazol on nerve growth factor was reversed by 8-cyclopentyl-1,3-dipropylxanthine, a selective A1 receptor antagonist, and enhanced by tempol administration. In spite of similar arrhythmic vulnerability during programmed stimulation in both the vehicle- and cilostazol-treated groups, cilostazol did not have proarrhythmic effects compared with milrinone. Conclusions: Unlike milrinone, cilostazol has therapeutic neutrality in arrhythmias because of adenosine uptake inhibition, which antagonizes the PDE-3-induced increase of sympathetic reinnervation via mediation of an adenosine A1 receptor-mediated antioxidation.

KW - Arrhythmia

KW - Myocardial infarction

KW - Phosphodiesterase-3 inhibitors

KW - Remodeling

KW - Sympathetic innervation

UR - http://www.scopus.com/inward/record.url?scp=84893001395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893001395&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-13-0749

DO - 10.1253/circj.CJ-13-0749

M3 - Article

C2 - 24304537

AN - SCOPUS:84893001395

VL - 78

SP - 366

EP - 376

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 2

ER -